Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

Completed · Phase 1

Conditions studied: Uterine Leiomyomata (Fibroids)

In brief

This is the first multiple-dose study in humans with PRA-027. This study will provide an assessment of the safety, tolerability, pharmacokinetics (how the drug is absorbed, metabolized and excreted by the body) and pharmacodynamics (a measure of whether the drug is active in the body) of PRA-027 after administration of 28 days of oral doses in women of childbearing potential (cycling) or postmenopausal women.

Key facts

Study ID
NCT00543790
Run by
Wyeth is now a wholly owned subsidiary of Pfizer
People needed
48
Starts
2007-11-01
Expected to finish
2008-12-01
Last updated by the study team
2010-10-28

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.